UTHR: United Therapeutics Corporation - Summary | Jitta

United Therapeutics Corporation

NASDAQ:UTHR

End of day
Dec 07, 2018
Price
$109.44
Loss Chance
37.9%
6.30
Updated 2018Q3
last month
Nov 05, 2018
JITTA SCORE
75.14%Below Jitta Line
Jitta Ranking
62 / 792
United States
?
NASDAQ, NYSE
1,290 / 4,765
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (61)
Recent Business Performance (5)
Financial Strength (100)
Return to Shareholders (42)
Competitive Advantage (93)
Jitta Signs
Revenue and Earning
201220132014201520162017
Revenue18.2622.1727.3532.0337.2139.90
Normalized Earning287.73174.56340.10433.24713.70558.88
EPS5.743.467.229.4716.6112.93
Consistent Growth in the past 5 years
Debt Level
20132014201520162017
Net Profit (mill.)174.56340.10433.24713.70558.88
Long Term Debt (mill.)0.000.000.000.00250.00
Low Long Term Debt
Share Repurchase
20132014201520162017
Common Shares (mill.)50.3947.1145.7642.9743.24
Every Year
CapEx
20132014201520162017
CapEx per Share0.631.011.090.882.00
Earning per Share3.467.229.4716.6112.93
Very Low
Operating Margin
20132014201520162017
Operating Margin (%)26.1941.8247.6966.4159.40
Declined
Recent Business Performance
Earning per ShareQ1Q2Q3Q4
20185.633.972.70-
20173.962.716.460.44
20165.254.713.792.57
Earning decline 21.69% in the last year
Key Stats
Jitta Score
Jitta Line
6.30
75.14%
1.82
0.86%
2.45
0.51%
Biotechnology
COMPANY DESCRIPTION
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company’s commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation has a licensing and collaboration agreement with MannKind Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension; and a licensing and commercialization agreement with Collplant for 3D bioprinting of solid-organ scaffolds for human transplants. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.